Chemometec A/S
CSE:CHEMM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Novoray Corp
SSE:688300
|
CN |
|
AltC Acquisition Corp
NYSE:OKLO
|
US |
|
T
|
Toyo Machinery & Metal Co Ltd
TSE:6210
|
JP |
|
Zhejiang Natural Outdoor Goods Inc
SSE:605080
|
CN |
|
KPA-BM Holdings Ltd
HKEX:2663
|
HK |
|
M
|
Mingyue Optical Lens Co Ltd
SZSE:301101
|
CN |
|
Pinnacle Investment Management Group Ltd
ASX:PNI
|
AU |
Chemometec A/S
Total Equity
Chemometec A/S
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Chemometec A/S
CSE:CHEMM
|
Total Equity
kr652.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
G
|
Gubra A/S
CSE:GUBRA
|
Total Equity
kr1.1B
|
CAGR 3-Years
120%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
Chemometec A/S
Glance View
Chemometec A/S, a Danish firm founded in the late 1990s, has carved a niche in the specialized world of biotech instrumentation. The company is renowned for developing and manufacturing high-precision cell counting and analysis instruments used predominantly in the life sciences sector. Its flagship product, the NucleoCounter®, has gained significant traction in laboratories and production facilities worldwide. This product stands out due to its accuracy and ease of use in counting various types of cells, whether in research or pharmaceutical production settings. Unlike traditional methods, Chemometec’s technology enables researchers to save time and reduce error, which is invaluable for laboratories looking to enhance their workflow efficiencies. Revenue for Chemometec is primarily generated through the sale of its advanced instruments and associated consumables, along with providing expert services that support the integration and maintenance of these technologies. The company's business model capitalizes on the growing global demand for sophisticated biomedical research tools, as innovation in the drug development and biotechnology sectors accelerates. By continuously investing in R&D, Chemometec not only ensures its products remain cutting-edge but also expands its applicability across new areas in the life sciences field. The strategy of maintaining close relationships with its end-users ensures that as the scientific landscape evolves, Chemometec is well-positioned to adapt and grow.
See Also
What is Chemometec A/S's Total Equity?
Total Equity
652.6m
DKK
Based on the financial report for Dec 31, 2025, Chemometec A/S's Total Equity amounts to 652.6m DKK.
What is Chemometec A/S's Total Equity growth rate?
Total Equity CAGR 5Y
24%
Over the last year, the Total Equity growth was 9%. The average annual Total Equity growth rates for Chemometec A/S have been 13% over the past three years , 24% over the past five years .